Mitchell S. Steiner
Mitchell S. Steiner, M.D., F.A.C.S. has focused his career in urologic oncology with emphasis in the diagnosis and treatment of prostate cancer. He received his M.D. from The University of Tennessee in 1986. He trained in Surgery and Urology and Molecular Biology at the Johns Hopkins School of Medicine and The Johns Hopkins Hospital. He also obtained a Molecular and Cell Biology Postdoctoral Fellowship as an American Foundation for Urologic Disease Scholar from Vanderbilt University from 1986 – 1995 and simultaneously had an appointment as Assistant Professor of Urology, Cell Biology, and Pathology.
He has served as the Chairman and Professor of the Department of Urology, Professor of Pharmacology, Director of Urologic Oncology and Research, Chair of Excellence in Urologic Oncology, at The University of Tennessee, Memphis from 1998-2004 and remained as Professor of Urology until 2013 Dr. Steiner is Board Certified in Urology (February 1997) and a Fellow of the American College of Surgeons (October 2000). Dr. Steiner is or has been a member of the Endocrine Society, American Society of Clinical Oncologists, American Association for Cancer Research, American Urological Society, Society for Basic Urology Research, Society for Urologic Oncology, and other prestigious societies. Dr. Steiner has conducted independent laboratory cancer research since 1980 and has been a recipient of NIH RO1s, Department of Defense, and CaP CURE Grants. He was a member of the Cancer Leukemia Group B Intergroup study section. He serves as a member of the editorial Board of Gene Therapy and Molecular Biology Journal, Editor-in-Chief of the World Journal of Urology, Section Editor of Prostate Cancer section of Current Opinions in Urology and was a member of the NIH, NCI, American Foundation for Urologic Disease, and American Cancer Society study sections. Dr. Steiner has authored over 300 abstracts and publications and has over 300 patents issued or pending. Dr. Steiner is a founder of GTx, Inc., which was formed in September 1997 and became a public company on the NASDAQ (GTXI) in 2004. GTx is a discovery and drug development company in the area of prostate cancer prevention, diagnosis, and treatment as well as oncology and cancer supportive care located in Memphis, Tennessee. Dr. Steiner served as the Vice Chairman and Chief Executive Officer of the company from 1997-2014. Dr. Steiner joined Opko Health, Inc. in 2014 and is responsible for medical affairs activities for the 4K Score Test, a new blood test that identifies the risk of aggressive prostate cancer.
Jay R. Newmark
Jay Newmark is Senior Director, Medical Affairs at OPKO Health, Inc., a Miami-based, multi-national pharmaceutical and diagnostics company. In his current role, Dr. Newmark handles medically-related activities pertaining to the recently introduced 4Kscore test, a novel biomarker for identification of aggressive prostate cancer. Prior to joining OPKO Health, Dr. Newmark was Associate Medical Director, Renal Care Medical Affairs at Abbvie where he was responsible for the creation and implementation of medical strategy for two pipeline compounds.
Prior to the spin-off of Abbvie from Abbott in 2013, Dr. Newmark served on several cross-functional teams for many Abbott pharmaceutical and diagnostic projects in all phases of clinical development.
Dr. Newmark’s background is in urology and urologic surgery, having trained at the The Johns Hopkins Hospital, Baltimore, MD. Before joining Abbott, he ran a busy urology medical practice in Chicago, IL where he treated patients with a full spectrum of urologic illnesses. During his medical career, Dr. Newmark also served on numerous hospital committees and as Medical Staff Vice-President, where he played a key role in addressing issues ultimately leading to improved quality of healthcare delivery and the overall patient hospital experience. Dr. Newmark holds a Bachelor of Science degree from Vanderbilt University, Nashville, Tennessee, a Medical Degree from the University of Michigan, Ann Arbor Michigan and a Master of Business Administration from the University of Chicago Booth School of Business, Chicago, Illinois.
Dr. Sant recently joined the Medical Affairs team at OPKO after a long academic and pharmaceutical industry career. He obtained his MD at Dublin University, Ireland and completed a general surgery residency at Albert Einstein College of Medicine in NY and urology residency at Tufts University School of Medicine in Boston, Massachusetts after which he joined the faculty at Tufts University.
He is former Whitney Professor and Chair of Urology, Tufts University School of Medicine (Distinguished Faculty Award), Urologist-in-Chief, Tufts Medical Center Hospitals and Urology Residency Program Director at Tufts University. He has held academic committee leadership positions with the National Institutes of Health (NIH-NIDDK), American Urological Association (AUA), Past-President New England Section AUA and the American Board of Urology (ABU) Examination Committee. Dr. Sant developed the first patient reported outcomes (PRO) instrument (O’Leary-Sant Symptom and Problem Scores) for interstitial cystitis and has an extensive publication record – 128 peer-reviewed publications, 36 book chapters, 2 textbooks (Pathophysiologic Principles of Urology; Interstitial Cystitis) and 10 Urology Journal Supplement Editorship. He is currently Adjunct Professor of Urology, Tufts University School of Medicine and a member of the editorial boards of the Canadian Journal of Urology, UroToday International, International Journal of Clinical Practice and Caribbean Medical Journal, Postgraduate Medicine and a member of the Board of Trustees, Academy of Physicians in Clinical Research (APCR)/ Association of Clinical Research Professionals (ACRP) and member of the Standards Committee, International Society of Medical Publication Professionals (ISMPP), Scholarship Committee, National Medical Fellowship (NFM), Scholarship Committee, US Section, International Society of Urology (SIU) and Scientific Advisory Board, Cellaynx. Dr. Sant has an extensive pharma and biotech experience as Head of Sanofi US Medical Affairs for Urology and Oncology and Head of Genzyme US and Global Medical Affairs for Rare Genetic Diseases. At Sanofi he launched 4 urology products – Taxotere, Jevtana and Eligard for metastatic prostate cancer and Uroxatral for benign prostatic hyperplasia and at Genzyme launched 2 rare diseases products (Lumizyme for Pompe Disease and Kynamro for familial hypercholesterolemia). He has led 6 disease state registries – 4 global at Genzyme and 2 at Sanofi – one for BPH and the other for Prostate Cancer.